Augmentation strategies: Focus on anxiolytics

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 7, 1996, Pages 25-32

  Joffe, Russell T ^a   Levitt, Anthony J ^b   Sokolov, Stephen T H ^b  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANXIOLYTIC AGENT;

ANXIETY NEUROSIS; DEPRESSION; DRUG USE; HUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; BENZODIAZEPINES; BUSPIRONE; DEPRESSIVE DISORDER; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; LITHIUM; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; TRIIODOTHYRONINE;

EID: 0029738080     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Fawcett J. Antidepressants: partial response in chronic depression. Br J Psychiatry 1994;165(suppl 26):37-41
2. Fawcett J, Kravitz HM. Treatment refractory depression. In: Schatzberg AF, ed. Common Treatment Problems in Depression. Washington, DC: American Psychiatric Press; 1985:1-27
3. Mintz J, Mintz LI, Arruda MJ, et al. Treatments of depression and the functional capacity to work. Arch Gen Psychiatry 1992;49:761-768
4. Keller MB. Depression: a long-term illness. Br J Psychiatry 1994;165 (suppl 26):9-15
5. Price LH. Lithium augmentation and tricyclic-resistant depression. In: Extein I, ed. Treatment of Tricyclic-Resistant Depression. Washington, DC: American Psychiatric Press; 1988:51-79
6. Fava M, Rosenbaum JF, McGrath PJ, et al. Lithium and tricyclic augmentation of fluoxetine for resistant major depression: a double-blind, controlled study. Am J Psychiatry 1994;151:1372-1374
7. Quitkin FM, Rabkin JG, Ross D, et al. Duration of antidepressant drug treatment what is an adequate trial? Arch Gen Psychiatry 1984;41:238-245
8. Thase ME, Frank E, Mallinger AG, et al. Treatment of imipramine-resistant recurrent depression, III: efficacy of monoamine oxidase inhibitors. J Clin Psychiatry 1992;53:5-11
9. Liebowitz MR, Quitkin FM, Stewart JW, et al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry 1988;45:129-137
10. Feighner JP. The role of venlafaxine in rational antidepressant therapy. J Clin Psychiatry 1994;55(9, suppl A):62-70
11. Reimherr FW, Wood DR, Byerley B, et al. Characteristics of responders to fluoxetine. Psychopharmacol Bull 1984;20:70-72
12. Roose SP, Glassman AH, Walsh BT, et al. Tricyclic nonresponders: phenomenology and treatment. Am J Psychiatry 1986;143:345-348
13. McGrath PJ, Stewart JW, Harrison W, et al. Treatment of tricyclic refractory depression with a monoamine oxidase inhibitor. Psychopharmacol Bull 1978;23:169-172
14. Beasley CM Jr, Sayler ME, Cunningham GE, et al. Fluoxetine and tricyclic refractory major depressive disorder. J Affect Disord 1990;20:193-200
15. Joffe RT, Levitt AJ, Sokolov STH, et al. Response to an open trial of a second SSRI in major depression. J Clin Psychiatry 1996;57:114-115
16. Schou M. Lithium and treatment-resistant depressions: a review. Lithium 1990;1:3-8
17. Heninger GR, Charney DS, Sternberg DE. Lithium carbonate augmentation of antidepressant treatment: an effective prescription for treatment-refractory depression. Arch Gen Psychiatry 1983;40:1335-1342
18. Cournoyer G, DeMontigny C, Ouellette J, et al. Lithium addition in tricyclic-resistant unipolar depression: a placebo-controlled study. In: Abstracts of Collegium Internationale Neuropsychopharmacology; June 19-23, 1984; Florence, Italy. Page 179
19. Kantor D, McNevin S, Leichner P, et al. The benefit of lithium carbonate adjunct in refractory depression: fact or fiction? Can J Psychiatry 1986;31: 1416-1418
20. Stein G, Bernadt M. Double-blind trial of lithium carbonate in tricyclic resistant depression. In: Birch NJ, ed. Lithium Inorganic Pharmacology and Psychiatric Use. Oxford, England: IRL Press; 1988:35-36
21. Zusky PM, Biederman J, Rosenbaum JF, et al. Adjunct low dose lithium carbonate in treatment-resistant depression: a placebo-controlled study. J Clin Psychopharmacol 1988;8:120-124
22. Schopf J, Baumann P, Lemarchand T, et al. Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition: results of a placebo-controlled, double-blind study. Pharmacopsychiatry 1989;22:183-187
23. Earle BV. Thyroid hormone and tricyclic antidepressants in resistant depression. Am J Psychiatry 1970;126:1667-1669
24. Ogura C, Okma T, Uchida Y, et al. Combined thyroid (triiodothyronine)-tricyclic antidepressant treatment in depressed states. Folia Psychiatry Neurol Jpn 1974;28:179-186
25. Banki CM. Triiodothyronine in the treatment of depression. Orv Hetil 1975;116:2543-2547
26. Banki C. Cerebrospinal fluid amine metabolites after combined amitriptyline-triiodothyronine treatment of depressed women. Eur J Clin Pharmacol 1977;11:311-315
27. 3 and antidepressants in depression. J Int Med Res 1979;7:138-146
28. Goodwin FK, Prange AJ Jr, Post RM, et al. Potentiation of antidepressant effects by L-triiodothyronine tricyclic nonresponders. Am J Psychiatry 1983;139:34-38
29. Schwarcz G, Hallirs A, Baxter L, et al. Normal thyroid function in desipramine nonresponders compared to responders by the addition of L-triiodothyronine. Am J Psychiatry 1984;141:1614-1616
30. 3 to potentiate tricyclic antidepressant response. J Affect Disord 1987;13:267-272
31. Thase ME, Kupfer DJ, Jarrett DB. Treatment of imipramine-resistant recurrent depression, I: an open clinical trial of adjunctive L-triiodothyronine. J Clin Psychiatry 1989;50:385-388
32. Joffe RT, Singer W. A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants. Psychiatry Res 1990;32:241-252
33. Joffe RT, Singer W, Levitt AJ, et al. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993;50:387-393
34. Nelson JC, Mazure CM, Bowers MB Jr, et al. A preliminary-open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991;48:303-307
35. Weilburg JB, Rosenbaum JF, Meltzer-Browdy S, et al. Tricyclic augmentation of fluoxetine. Ann Clin Psychiatry 1991;3:209-213
36. Weilburg JB, Rosenbaum JF, Bieterman J, et al. Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. J Clin Psychiatry 1989;50:447-449
37. Jacobsen FM. Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry 1991;52:217-220
38. Warneke L. Psychostimulants in psychiatry. Can J Psychiatry 1990;35:3-10
39. Young SN. Use of L-tryptophan in combination with other antidepressant treatments. J Psychiatry Neurosci 1991;16:241-246
40. Fontaine R, Ontiveros A, Elie R, et al. Lithium carbonate augmentation of desipramine and fluoxetine in refractory depression. Biol Psychiatry 1991; 29:946-948
41. Joffe RT. Triiodothyronine potentiation of fluoxetine in depressed patients. Can J Psychiatry 1992;37:48-50
42. Bakish D. Fluoxetine potentiation by buspirone: three case histories. Can J Psychiatry 1991;36:749-750
43. Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry 1993;54: 269-271
44. Joffe RT, Bakish D. Combined SSRI-moclobemide treatment of psychiatric illness. J Clin Psychiatry 1994;55:24-25
45. Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 1994;51:251-252
46. Feighner JP, Boyer WF, Tyler DL, et al. Adverse consequences of fluoxetine-MAOI combination therapy. J Clin Psychiatry 1990;51:222-225
47. Neuvonen PJ, Pohjola-Sintonen S, Take U, et al. Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses [letter]. Lancet 1993;342:1419
48. Joffe RT. Triiodothyronine potentiation of the antidepressant effect of phenelzine. J Clin Psychiatry 1988;49:409-410
49. Stern SL, Mendels J. Drug combinations in the treatment of refractory depression: a review. J Clin Psychiatry 1981;42:368-373
50. Feighner JB, Herbstein J, Damlouji N. Combined MAOI, TCA and direct stimulant therapy of treatment-resistant depression. J Clin Psychiatry 1985;46:206-209
51. Joffe RT, Levitt AJ, Bagby RM, et al. Predictors of response to lithium and triiodothyronine augmentation of antidepressants and tricyclic nonresponders. Br J Psychiatry 1993;163:574-578
52. Nelson JC. Combined treatment strategies in psychiatry. J Clin Psychiatry 1993;54(9, suppl):42-49
53. Smith BD, Salzman C. Do benzodiazepines cause depression? Hosp Community Psychiatry 1991;42:1101-1102
54. Feighner JP, Brauzer B, Gelenberg AJ, et al. A placebo-controlled multicentre trial of limbitrol versus its components (amitriptyline and chlordiazepoxide) in the symptomatic treatment of depressive illness. Psychopharmacology (Berl) 1979;621:217-225
55. Fawcett J, Edwards JH, Kravits HM, et al. Alprazolam: an antidepressant? alprazolam, desipramine and alprazolam-desipramine combination in the treatment of adult depressed outpatients. J Clin Psychopharmacol 1987;7:295-310
56. Napoliello MJ, Domantay AG. Buspirone: a world-wide update. Br J Psychiatry 1991;159(suppl 12):40-44